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Abstract
Background: p66Shc, an isoform of Shc adaptor proteins, mediates diverse signals, including cellular stress and mouse
longevity. p66Shc protein level is elevated in several carcinomas and steroid-treated human cancer cells. Several lines of
evidence indicate that p66Shc plays a critical role in steroid-related carcinogenesis, and steroids play a role in its elevated
levels in those cells without known mechanism.
Methods and Findings: In this study, we investigated the molecular mechanism by which steroid hormones up-regulate
p66Shc protein level. In steroid-treated human prostate and ovarian cancer cells, p66Shc protein levels were elevated,
correlating with increased cell proliferation. These steroid effects on p66Shc protein and cell growth were competed out by
the respective antagonist. Further, actinomycin D and cyclohexamide could only partially block the elevated p66Shc protein
level by steroids. Treatment with proteasomal inhibitors, but not lysosomal protease inhibitor, resulted in elevated p66Shc
protein levels, even higher than that by steroids. Using prostate cancer cells as a model, immunoprecipitation revealed that
androgens and proteasomal inhibitors reduce the ubiquitinated p66Shc proteins.
Conclusions: The data collectively indicate that functional steroid receptors are required in steroid up-regulation of p66Shc
protein levels in prostate and ovarian cancer cells, correlating with cell proliferation. In these steroid-treated cells, elevated
p66Shc protein level is apparently in part due to inhibiting its ubiquitination. The results may lead to an impact on
advanced cancer therapy via the regulation of p66Shc protein by up-regulating its ubiquitination pathway.
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Introduction
Shc (Src homolog and collagen homolog) proteins are identified
as adaptor molecules mediating tyrosine phosphorylation signaling
[1]. ShcA, the Shc proteins in mammalian cells, exists in three
different isoforms with molecular masses of 46, 52 and 66 kDa. All
isoforms contain three functional domains – an SH2 domain, a
PTB domain and a CH1 domain with three conserved tyrosine
residues that are phosphorylated in response to various signals [1].
Additionally, p66Shc has a unique CH2 domain at the N-
terminus, which contains a serine residue (Ser-36) that can be
phosphorylated under stress signals [2]. Different members of the
Shc proteins exhibit distinct expression patterns and biological
functions. For example, p52Shc and p46Shc are expressed in most
cells, while p66Shc protein is expressed predominantly in epithelial
cells [3]. Both p52Shc and the majority of p66Shc are distributed
throughout the cytosol, whereas a fraction of p66Shc and p46Shc
localize to mitochondria [4,5]. Shc proteins were first described as
adaptor proteins that bridge the growth factor receptor-bound
protein (grb2)-son of seven less (sos1) complex to the phosphor-
ylated receptor tyrosine kinase (RTK), resulting in activation of the
membrane-bound GTPase ras [6]. Thus, Shc protein plays critical
roles in diverse signal pathways.
p66Shc is unique among ShcA proteins because of its distinct
structural and functional features [5]. Functionally, p66Shc, but
not other two ShcA proteins, play a pivotal role in regulating the
intracellular level of reactive oxygen species (ROS) [5,7]. By virtue
of its ability to modulate ROS levels, p66Shc plays an important
role in the aging and age-associated bioprocesses including, for
example, vascular dysfunction [8]. In mammals, p66Shc functions
as a longevity gene [2]. Nevertheless, its role in human longevity
requires further investigation.
Despite the fact that results of many studies indicate p66Shc as a
mediator of apoptosis, recent advances associate p66Shc with
human epithelial cell proliferation and carcinogenesis [5]. For
example, in ovarian carcinoma cell lines, p66Shc protein level
positively correlates with ErbB-2 expression, a prognostic marker
for ovarian cancer [9]. In breast cancer, p66Shc protein level is
increased in cell lines with highly metastatic ability and is elevated
in lymph node-positive tumors [10]. Nevertheless, a negative
correlation between p66Shc expression and primary tumor of
breast cancer has been reported [11,12]. It should be noted, in that
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utilized [12]. Further studies are thus required to define its role in
breast carcinogenesis. Importantly, in prostate, ovarian, thyroid
and colon carcinoma tissues, p66Shc protein levels are higher in
cancerous cells than that in the adjacent non-cancerous cells
[10,13,14,15,16]. In prostate cancer cell lines, p66Shc protein level
positively correlates with their growth rates [14,17]. Further,
growth stimulation of prostate, testis and breast cancer cell lines
with respective steroid hormones is accompanied by an increase of
p66Shc protein level [14], implying its function in steroid-induced
proliferation. Evidently, p66Shc knockdown is associated with
diminished cell growth [17]. Thus, p66Shc signaling plays a
functional role in regulating the proliferation and the carcinogen-
esis of diverse cell types. However, the regulatory mechanism of
p66Shc protein level related to its function remains an enigma.
The expression level of a protein can be controlled through the
regulation of its transcription, translation and stability via
degradation process. Although several factors including epigenetic
regulation have been reported to affect p66Shc expression
[18,19,20], the specific mechanisms underlying how p66Shc
protein, the functional molecule, is regulated remain to be
elucidated. Targeting of cellular proteins for proteasomal
proteolysis marked by ubiquitination is a highly complicate and
tightly regulated process [21]. Protein ubiquitination is a signal for
target recognition and ATP-dependent proteolysis by the 26S
proteasome [22,23,24]. Ubiquitin, an evolutionarily conserved
protein of 76 residues, exhibits diverse cellular functions. It can be
covalently conjugated to lysine residues in target proteins including
marking mono or polyubiquitination of proteins [24]. Polyubiqui-
tination of proteins in general is widely acknowledged as a signal
for degradation by the proteasome [25], while monoubiquitina-
tion, although presently ill-defined, has been shown to influence
numerous cellular events, including endocytosis and meiosis
[26,27]. Since in steroid hormones-treated cells, p66Shc protein
levels are elevated, correlating with cell proliferation, we
investigate the molecular mechanism by which steroids up-
regulate p66Shc protein. Understanding this machinery may lead
to develop therapeutic strategies toward steroid-regulated cancers.
Materials and Methods
Reagents and antibodies
Fetal bovine serum (FBS), gentamicin, L-glutamine and RPMI
1640 medium were obtained from Invitrogen (Carlsbad, CA,
USA). Charcoal/dextran-treated FBS was purchased from Atlanta
Biologicals (Lawrenceville, GA, USA). N-carbobenzoxyl-L-leuci-
nyl-L-leucinyl-L-norleucinal (MG 132), lactacystin, leupeptin and
actinomycin D (Act D) were from Calbiochem (San Diego, CA).
Polyclonal antibody (Ab) recognizing all three Shc isoforms of Shc
protein was from Upstate Biotechnology Inc. (Lake Placid, NY,
USA). Horseradish peroxidase-conjugated anti-mouse and anti-
rabbit IgG Abs were from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-ubiquitin and anti-b-actin Ab, 5a-dihydrotestoesteron
(DHT), estrogen (E2), tamoxifen, cyclohexamide (CHX), protease
inhibitor cocktail, pancreatic bovine insulin, Protein A-Sepharose
coated beads were purchased from Sigma (St Louis, MO, USA).
All other chemicals were as described previously [14,17,28,29].
Cell lines
LNCaP-FGC human prostate cancer cells, CaOV-3 and OVCAR-
3 human ovarian cancer cell lines were originally purchased from the
American Type Culture Collection( R o c k v i l l e ,M D ,U S A ) .L N C a PC -
33 cells are androgen-sensitive and routinely maintained in phenol red-
positive RPMI1640medium supplementedwith 5% FBS (v/v), 2 mM
glutamine and 50 mg/ml gentamicin [28]. CaOV-3 cells are routinely
maintained in phenol red-positive RPMI 1640 medium supplemented
with 10% FBS (v/v), 2 mM glutamine and 50 mg/ml gentamicin.
OVCAR-3 cells are routinely maintained in phenol red-positive RPMI
1640 medium supplemented with 20% FBS (v/v), 2 mM glutamine,
pancreatic bovine insulin (10 mg/ml) and gentamicin (50 mg/ml). Cells
were split once per week, which was defined as one passage. LNCaP
cells with passage numbers less than 33 were designated as C-33
[28,30]. For DHT and E2 treatments, LNCaP C-33, CaOV-3 and
OVCAR-3 cells were steroid-starved for 48 h in a steroid-reduced
medium, i.e., phenol red-free RPMI 1640 medium containing 5%
charcoal/dextran-treated FBS (v/v), 2 mM glutamine and gentamicin
(50 mg/ml). LNCaP cells were exposed to DHT (10 nM), CaOV-3
and OVCAR-3 cells were exposed to E2 (10 nM), and cells were
harvested after various periods of time, as indicated in each
experiment. For treating with RNA and protein de novo biosynthesis
inhibitors, cells were pretreated for 1 h with Act D and CHX prior to
the addition of DHT in the same medium for an additional 24 h.
Immunoblotting
Briefly, subconfluent cells were gently rinsing twice with ice-cold
20 mM HEPES-buffered saline, pH 7.0, scraped, and cell pellet
was lysed in ice-cold high-stringent cell lysis buffer containing
protease and phosphatase inhibitors. The detailed protocols for
immunoblotting were described previously [14,28,29]. For semi-
quantifying the intensity of hybridization bands, the ImageJ.exe
program (http://rsb.info.nih.gov) was used.
Cell growth determination
To determine the growth rate, cells were seeded on six-well
culture plates and maintained in their respective culture medium.
At the specific time point, attached cells was harvested by
trypsinization and the cell number was measured by a cell counter
cellometer
TM Auto T4 (Nexcelom Bioscience, USA).
Immunoprecipitation
To immunoprecipitate p66Shc protein, cells were washed with
ice-cold 20 mM HEPES-buffered saline, pH 7.0, collected and
pelleted by centrifugation, and lysed on ice for 20 min with lysis
buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5%
NP-40, protease inhibitor cocktail). Abs to Shc protein (3 mg) and
to ubiquitin (20 ml) were first respectively incubating with Protein
A-Sepharose beads (50 ml of 10% suspension) in 500 ml of lysis
buffer for 1 h at 4uC. Cell lysates (0.3 mg) were incubated with
Abs coated in Protein A-Sepharose beads in a volume of 500 mla t
4uC for 2 h. Beads were washed three times (1 ml each) with ice-
cold lysis buffer. Immunoprecipitated proteins were eluted by
heating at 95uC for 5 min in Laemmli sample buffer (50 mM Tris
HCl, pH 6.8, 2% SDS (v/v), 0.001% bromophenol blue, 10%
glycerol (v/v), 100 mM dithioerithreitol) [31].
Statistical analysis
Each set of experiments was repeated at least 3 times and the
mean and standard error values were calculated. The significance
of difference (P-value) was calculated using independent t-test and
the P-value less than 0.05 was considered as significant.
Results
Effects of steroids on p66Shc protein levels and the
proliferation of prostate and ovarian cancer cells
LNCaP C-33 cells are androgen-sensitive cells with a slow
growth rate and express a low level of p66Shc protein. Since
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[14], we investigated the molecular mechanism by which p66Shc
protein is elevated in DHT-treated LNCaP cells. As shown in
Fig. 1A (lane #3 of left panel), in DHT-treated LNCaP C-33 cells,
p66Shc protein levels, but not p52 or p46 Shc protein, were
elevated as observed previously [14]. The hybridization band was
semiquantified by scanning and then normalizing to that of b-
actin. The data validated the specific DHT effect on p66Shc
protein, but not p52 or p46Shc, by over 2-fold elevation (lane #3,
Fig. 1A). Concurrently, the proliferation of DHT-treated cells was
increased (Fig. 1A, column #3 of right panel). On contrast, in the
presence of casodex, an AR antagonist used in clinical androgen
Figure 1. Effects of steroids on p66Shc protein levels in PCa and OVa cells and their proliferation. LNCaP C-33 and CAOV-3 cells were
plated in duplicates in the regular medium as described in the methods for 72 h and then maintained in a steroid-reduced medium for 48 h. Cells
were treated with steroids plus or minus the corresponding antagonists as specified in each figure for 48 h. After harvested, lysates were analyzed by
western blotting with Abs against total Shc and b-actin protein, respectively. The level of b-actin protein was detected as a loading control. The
intensity of each Shc protein hybridization band was semiquantified, and the ratio to the corresponding b-actin protein was calculated and then
normalized to that of corresponding control cells which received the solvent alone. To determine cell growth, cell number was analyzed by cell
counting. The figure is a representative of three sets of independent experiments in duplicates and the cell growth is expressed as means 6 SE (n=3).
(A) LNCaP C-33 cells were treated with or without DHT (10 nM), plus or minus casodex (10 mM) for 48 h. Left panel: Lane 1, cells received EtOH as a
control; Lane 2, cells received DMSO as a control; Lane 3, cells received DHT in EtOH; Lane 4, cells received casodex in DMSO; Lane 5, cells received
both DHT & casodex. Right panel: Cell growth was analyzed by cell counting. (n=263, **P,0.001). (B) Left panel: CaOV-3 cells treated without or
with E2 (10 nM), tamoxifen (0.1 and 1 mM) for 48 h. Right panel: Cell growth was analyzed by cell counting. (n=263, *P,0.05). SD, Standard
deviation.
doi:10.1371/journal.pone.0015942.g001
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abolished (Fig. 1A, lane #5 of left panel) and cell growth was
diminished (Fig. 1A, column #5 of right panel). Thus, casodex
blocks the up-regulatory effect of DHT on p66Shc protein as well
as the growth of LNCaP C-33 cells. The data indicate that AR
activity is required for androgen-mediated up-regulation of
p66Shc protein level.
We further investigated whether E2 also could up-regulate
p66Shc protein level in ovarian cancer cells as that by DHT in
prostate cancer cells. Ovarian cancer CaOV-3 cells are estrogen-
sensitive cells and express a high basal level of p66Shc protein. In
E2-treated CaOV-3 cells, p66Shc protein levels were elevated,
higher than that in control cells (Fig. 1B, left panel). The only
approximately 50% elevation by E2 was at least in part due to the
high basal level in the absence of E2 (Fig. 1B). In the presence of
tamoxifen, an antagonist of estrogen receptor (ER), the elevated
p66Shc level was reduced in a dose-dependent fashion (Fig. 1B, left
panel). The specific effect by E2 on p66Shc protein level was further
validated by semiquantifying the hybridization bands (Fig. 1B, left
panel). In parallel, E2 promoted cell growth, which was competed
out by tamoxifen (Fig. 1B, right panel). Thus, tamoxifen abolishes
the up-regulatory effect of E2 on p66Shc protein in CaOV-3 cells,
indicating that ER activity is required for E2-elevated p66Shc
protein levels as well as cell proliferation. The data together show
that steroids via the corresponding receptors up-regulate p66Shc
protein levels, correlating with stimulated cell proliferation.
Effects of de novo biosynthesis inhibitors on p66Shc
protein level by androgens
p66Shc protein plays a critical role in steroid-stimulated cell
growth [32]. Due to the importance of p66Shc protein in growth
regulation, we investigated whether androgens up-regulated the
biosynthesisof p66Shcprotein.In LNCaPC-33 cells,intheabsence
of androgen, 80% and 70% of the basal p66Shc protein level was
reduced byActD andCHX, inhibitorsofdenovo RNAsynthesisand
de novo protein synthesis, respectively (Fig. 2). In this set of
experiments, in the presence of DHT alone, p66Shc protein level
was elevated by about 2 folds, and Act D and CHX could only have
a partial effect on reducing DHT-induced p66Shc protein levels in
these cells. In comparison, DHT treatment increased cPSA, an
androgen-regulated protein, by up to 3-fold and Act D and CHX
treatments resulted in a great decrease of PSA (Fig. 2). Interestingly,
in the presence of DHT, Act D and CHX had only marginal effects
on decreasing AR protein levels. Thus the data indicated that in
DHT-treated cells, the elevation of p66Shc protein level could not
be explained by de novo biosynthesis alone.
Effects of proteasomal and lysosomal protease inhibitors
on p66Shc protein level in PCa cells
We investigated the involvement of protein degradation
pathway in up-regulating p66Shc protein level by DHT. p66Shc
protein was analyzed in the presence of proteasomal inhibitors
MG 132 (0.01 to 10 mM) and lactacystin (0.1 to 10 mM) and a
lysosomal protease inhibitor leupeptin (1 to 50 mM) under a
steroid-reduced condition. As a positive control, cells were treated
with 10 nM DHT. As shown in Fig. 3A, p66Shc protein level was
elevated in the presence of proteasomal inhibitors, essentially
following a bell-shaped dose-dependent fashion. In MG 132- and
lactacystin-treated cells, the p66Shc protein level was even higher
than that in DHT-treated cells. Nevertheless, leupeptin treatment
didn’t cause an elevation of p66Shc protein level (Fig. 3B). Instead,
the p66Shc protein level was decreased at high concentrations of
leupeptin; while leupeptin did not have an effect on p52Shc,
p46Shc or b-actin protein levels. The data indicate that DHT
Figure 2. Effects of de novo biosynthesis inhibitors on p66Shc protein levels. LNCaP C-33 cells were plated in the regular culture medium
for 72 h. After steroid starvation for 48 h, cells were treated with or without DHT (10 nM), 5 mg/ml actinomycin D (Act D) or 10 mg/ml cyclohexamide
(CHX) as specified in the figure for 24 h. After harvesting, cell lysates were analyzed by western blotting with Abs against total Shc, prostate-specific
antigen (PSA), androgen receptor (AR) and b-actin protein, respectively. The level of b-actin protein was detected as a loading control. The intensity of
p66Shc hybridization band was semiquantified, and the ratio to the corresponding b-actin protein was calculated and then normalized to that of
control LNCaP cells which received the solvent alone. The figure is a representative of four sets of independent experiments. SD, Standard deviation.
doi:10.1371/journal.pone.0015942.g002
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proteasomal pathway.
Kinetic analyses of androgens and proteasomal inhibitors
on p66Shc protein level in PCa cells
Effects of DHT and proteasomal inhibitors on p66Shc protein
levels were examined kinetically in LNCaP C-33 cells. As shown in
Figs. 4A and 4B, p66Shc protein levels were elevated in DHT-,
MG132- and lactacystin-treated cells, following the time course.
Semiquantitative analyses of the intensity of p66Shc protein
hybridization bands revealed that the level of p66Shc protein was
elevated starting at 6 h after treatment by both DHT and MG 132
and through 48 h treatment. Further, p52Shc and p46Shc protein
levels were remained essentially the same. Thus, the observed
elevation of p66Shc by androgens in LNCaP cells is at least in part
regulated at the posttranslational level.
Effect of estrogens and proteasomal inhibitors on p66Shc
protein level in ovarian carcinoma cells
We investigated whether proteasomal inhibitors also could have
an effect on p66Shc protein level in ovarian cancer cells. As shown
in Fig. 5A, despite a high basal level in the absence of E2, p66Shc
protein levels were further elevated in E2- and proteasomal
inhibitors-treated CaOV-3 cells. In OVCAR-3 cells, another
estrogen-sensitive ovarian cancer cell line that expresses a very low
level of p66Shc, E2 treatment greatly increased p66Shc protein
level. Similarly, in the presence of proteasomal protease inhibitors,
p66Shc protein level elevated, even higher than that by E2 (Fig. 5).
Thus, in E2- and proteasomal inhibitors-treated ovarian cancer
cells, p66Shc protein levels were elevated, apparently due to
reduced degradation.
Androgen effect on the ubiquitination of p66Shc protein
Since DHT and E2 treatments up-regulate p66Shc protein level
at least in part via the same pathway, we used LNCaP C-33 cells
as the model system for further analysis. We investigated DHT
effects on the proteasomal degradation pathway in LNCaP C-33
cells by analyzing ubiquitinated-p66Shc protein complexes. MG
132-treated LNCaP C-33 cells were used as a control. p66Shc
protein in DHT- and MG 132-treated LNCaP C-33 cell lysates
were immunoprecipitated by Abs to Shc proteins and the
immunoprecipitated complex was analyzed by immunoblotting
with anti-Shc Abs and anti-ubiquitin Abs, respectively. Under the
steroid-reduced condition, p66Shc protein was highly ubiquiti-
nated as indicated by the appearance of high mol wt. complexes
that were reacted with anti-ubiquitin Ab (Fig. 6B, control). The
ubiquitinated-p66Shc protein complexes were greatly decreased in
DHT- and MG 132-treated LNCaP cells (Fig. 6A & 6B).
Semiquantitative analyses revealed that over 70% of complex I
Figure 3. Dosage effects of proteasomal inhibitors on p66Shc
protein levels. LNCaP C-33 cells were seeded in regular culture
medium for 72 h, steroid starved for 48 h and then cells were treated
with or without 10 nM DHT or different concentrations of (A) MG132
(0.01 to 10 mM), (B) lactacystin (0.1 to 10 mM) and (C) leupeptin (1 to
50 mM) for 24 h. Cells were harvested and lysates were analyzed by
western blotting with Abs against total Shc protein and b-actin protein,
respectively. The level of b-actin protein was detected as a loading
control. The figure is a representative of at least five sets of
independent experiments.
doi:10.1371/journal.pone.0015942.g003
Figure 4. Kinetic analyses of DHT and proteasomal inhibitors
on p66Shc protein levels. LNCaP C-33 cells were plated in regular
medium for 72 h, steroid starved for 48 h, and then cells were treated
without or with DHT (10 nM), MG 132 (0.5 mM) or Lactacystin (1 mM) for
various time periods as indicated in the figure. Cells were harvested and
lysates were analyzed by western blotting with Abs against total Shc
protein and b-actin protein, respectively. The level of b-actin protein
was detected as a loading control. The figure is a representative of three
sets of independent experiments. (A) Cells were treated with DHT
(10 nM) or MG132 (0.5 mM) and harvested at 6 h, 12 h, 18 h and 24 h
and (B) cells were treated with DHT (10 nM), MG132 (0.5 mM) or
Lactacystin (1 mM)) and harvested at 48 h after treatment.
doi:10.1371/journal.pone.0015942.g004
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(Figs. 6A and 6B). To further confirm the ubiquitination of p66Shc
protein in the SR-condition, total ubiquitinated proteins were
immunoprecipitated by an anti-ubiquitin Ab followed by immu-
noblotting with Abs specific to Shc proteins. Western blot analyses
revealed the presence of high molecular weight p66Shc in
immunoprecipitated ubiquitin-conjugated proteins, which was
reduced by DHT, although to a lesser degree than that shown
in Figs. 6A and 6B, and was abolished by MG 132 (Fig. 6C). These
data together indicate that in DHT-treated LNCaP C-33 cells, the
ubiquitinated p66Shc protein is decreased, as seen in the
proteasome inhibitors-treated cells.
Discussion
p66Shc protein plays a critical role in regulating oxidative stress
response and life span in mammals. It is also shown to be
correlated with the progression of several steroid-regulated tumors
[5]. Due to the potential importance of p66Shc protein involved in
diverse signal activities including steroid-regulated carcinogenesis,
we investigate the molecular mechanism by which steroid
hormones up-regulate p66Shc protein level.
Our data clearly show that DHT treatment of androgen-sensitive
prostate cancer LNCaP C-33 cells leads to an increase in p66Shc
protein, but not p52Shc or p46Shc protein, and cell proliferation
(Fig. 1A) [14]. This up-regulatory effect of DHT on p66Shc and cell
growth is abolished by casodex (Fig.1A), an antagonist to AR in clinical
androgen-ablation therapy for advanced PCa [33]. Apparently, AR
activity is required in DHT up-regulating p66Shc protein. Similarly,
E2 up-regulation of p66Shc protein levels in ovarian cancer cells
(Fig. 1B) and breast carcinoma cells [14] require functional ER,
correlating with cell proliferation (Fig. 1B) [14]. The data collectively
indicate that p66Shc plays a critical role in regulating the growth rate of
these cells [17,32]. Thus, it is imperative to delineate steroid regulation
of its protein. Interestingly, while Act D can greatly block DHT effect
on elevating p66Shc and cPSA protein levels; CHX can only have a
partial inhibitory activity on DHT-induced p66Shc protein, differing
from CHX effect on DHT-induced cPSA protein level (Fig. 2). Since
DHT and E2 up-regulating p66Shcproteinsare not entirely through de
novo biosyntheses alone (Fig. 2), androgens and estrogens up-regulate
p66Shc protein at least in part via post-translational regulation.
Previous studies indicated that tumor suppresser p53 protein
increasesp66Shcproteinstabilityinmouseembryonicfibroblastcells,
apparently signaling for apoptotic pathway [34]. Nevertheless, our
study revealed that DHT treatment does not increase p53 protein
levels in LNCaP C-33 cells (data not shown) [32], whereas DHT
increases p66Shc protein levels and cell proliferation. p53 is a tumor
suppressor and its expression iseither down regulated or the protein is
mutated in about 60% of advanced cancer cells [35], whereas p66Shc
protein leveliselevated inseveraltypesofcancers [5,14,15,16]. Inthis
study, DHT and E2 respectively up-regulate p66Shc protein level in
PCa and OVa cells. In these growth-stimulated cells, p53 protein
would not be elevated, while p66She is elevated. These data together
indicate that DHT and E2 increase p66Shc protein level in LNCaP
andovariancancercells,respectively,viaap53-independentmanner.
Ser36 phosphorylation of p66Shc is proposed to signal the
translocation of p66Shc to mitochondria for apoptotic pathway
[36]. In the steroid-reduced condition, as an androgen-sensitive cell,
Ser36 phosphorylation at p66Shc protein is at a high level in LNCaP
C-33 cells (data not shown) [32]. This elevated phosphorylation is
decreased in the presence of DHT, a survival factor for those cells,
and p66Shc protein level is elevated. Interestingly, in the presence of
proteasomal inhibitors, Ser36 phosphorylation is also diminished
without known mechanism (data not shown). Alternatively, Ser54
and Ser286 phosphorylation may play a role in steroid-induced
p66Shc protein stability [20]. Further investigation is thus required to
determine the functional amino acid residue in regulating its protein
stability in different cell types under different growth conditions.
Interestingly, steroids can interact with the proteasomal degra-
dation pathway, leading to the activation of AR signaling [37]. Our
results (Figs. 3 and 4) clearly show that in the presence of
proteasome inhibitors MG 132 and lactacystin, but not lysosomal
protease inhibitor leupeptin, p66Shc protein level is elevated to a
level that is even higher than DHT effects. In the presence of
proteasomal inhibitors or steroids, p66Shc protein levels are
elevated in prostate and ovarian cancer cells, following a dose-
dependent and a time course-dependent fashion. These data clearly
indicate that p66Shc is degraded by the proteasomal pathway, and
steroid hormones may prevent p66Shc protein from degradation.
The ubiquitin-proteasome pathway is a major pathway for
intracellular protein degradation. Protein substrates are first
‘‘marked’’ with poly-ubiquitin chains and then degraded to
peptides and free ubiquitin by a large multimeric protease, the
proteasome, which exists within all eukaryotic cells [38]. There are
two known sequences that are required for proteasomal degrada-
tion. One is the PEST sequence [39] and the other is the
destruction box [40]. While there is no identifiable destruction box
within the sequence of p66Shc protein, p66Shc has two PEST
Figure 5. Effects of E2 and proteasomal inhibitors on p66Shc
protein levels in ovarian carcinoma cells. CaOV-3 and OVCAR-3
cells were plated in regular medium for 72 h and steroid starved for
48 h. (A) CaOV-3 cells were treated with or without E2 (10 nM), MG 132
(0.01, 0.1 mM) or Lactacystin (0.1, 0.5 mM) for 48 h and (B) OVCAR-3 cells
were treated with or without E2 (10 nM), MG 132 (0.01, 0.1 mM) or
Lactacystin (0.05, 0.1 mM) for 48 h. Cells were harvested and lysates
were analyzed by western blotting with Abs against total Shc protein
and b-actin protein, respectively. The level of b-actin protein was
detected as a loading control. The figure is a representative of three sets
of independent experiments.
doi:10.1371/journal.pone.0015942.g005
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domain and amino acids 328 through 347 in the CH1 domain
[20]. Interestingly, Ser36 and Ser54 are located within the first
PEST motif. Further experiments are required to clarify if both
PEST motifs are responsible for p66Shc degradation.
Our results reveal that ubiquitinated p66Shc proteins in LNCaP
C-33 cells are of high molecular mass (.100 kDa) (Fig. 6). Such large
conjugates have been shown in vitro to be preferentially degraded by
the 26S (1500 kDa) proteasome complex [41,42,43,44]. Further-
more, ubiquitinated p66Shc proteins are decreased in DHT- and
MG132-treated cells (Fig. 6), whereas the amounts of the non-
ubiquitinated66 kDaproteinsincreaseinthesecells(Figs.3&4).The
data also indicate that such high molecular mass of Ub-protein
conjugates accumulate rapidly (observed at 6 h) in steroid-reduced,
stressful condition in which most cellular activities are suppressed,
comparing to its half life of 4.5 h in regular growth condition [20].
These high-molecular-mass conjugates apparently represent the
multi poly-ubiquitinated p66Shc proteins marked for degradation.
Further experiments should determine the molecular structure of
these complexes. These data together support the notion that DHT-
induced elevation of p66Shc protein level in LNCaP C-33 cells is
through inactivation of proteasomal pathway by inhibiting its
ubiquitination. Similarly, E2 modulates p66Shc protein levels in
ovarian cancer cells apparently by preventing it from proteasomal
degradation (Fig. 5). These observations also raise an interesting
question if steroids and proteasomal inhibitors can also suppress the
ubiquitination processfor blocking the proteasomal activity. Our data
thus reveal a novel non-genomic regulatory mechanism by steroid
hormone on p66Shc protein, a functional protein involving in diverse
cellular activities. Due to the potential importance of p66Shc in
carcinogenesis and tumor progression of diverse cancer types,
targeting to the proteasomal pathway to facilitate p66Shc degrada-
tion can be an alternative approach to advanced cancer therapy.
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Figure 6. Androgen effects on the ubiquitination of p66Shc proteins. LNCaP C-33 cells were plated in regular medium for 72 h, steroid
starved for 48 h and then treated with or without DHT (10 nM) and MG 132 (0.5 mM) as a positive control for 24 h. Cell were harvested in lysis buffer.
Total cellular lysates (300 mg proteins) were reacted with (A&B ) anti-Shc or (C) anti-Ubiqutin Ab (3 mg each), and followed by Protein A–Sepharose
beads. The immune complexes were analyzed by immunoblotting with (A) anti-Shc Ab, (B) anti-ubiquitin Ab and (C) anti-Shc Ab. The positions of
p66Shc and p66Shc/Ub-protein complex are indicated by arrow-heads. The figure is a representative of four sets of independent experiments.
doi:10.1371/journal.pone.0015942.g006
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